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Paediatric and geriatric patients experience swallowing difficulties for traditional oral dosage 
forms, such as tablets. Further, microbial contamination, chemical stability, unpleasant taste and 
swallowing large volumes of fluids have led to low therapeutic efficacy and patient non-
compliance. The emergence of oral thin films has resulted in dramatic improvements in 
compliance and drug therapy outcomes in paediatric and geriatric patients. Oral thin films do not 
require water for administration, are readily hydrated upon contact with saliva, adhere to the 
mucosa and disintegrate ideally under one minute. This article provides an overview of oral thin 
films, modern trends in their formulation and characterisation, available commercial products, 
information to fill knowledge gaps and future potential and economic prospects of oral thin film 
technology, with emphasis on their use in the paediatric and geriatric patient groups.  
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The oral route remains the most widely used avenue of administering drugs aimed at achieving 
systemic effect, even though a few drugs are intended to dissolve in the mouth for quicker 
absorption or to achieve a local effect in the oral cavity [1, 2]. The oral route is the simplest, 
cheapest, most convenient and safest mode of administering drugs. Most clinicians and drug 
manufacturers prefer the oral route because of its high levels of acceptability by patients, therefore 
more than 50% of all the available pharmaceutical formulations are presented as oral dosage forms. 
Despite its wide acceptability, it is plagued by delayed onset of action, irregular drug absorption 
or lower bioavailability due to the first-pass metabolic effect, dysphagia, as well as the 
unpalatability of some active pharmaceutical ingredients (APIs) [1]. Although liquid formulations 
such as suspensions, emulsions and syrups are easy to swallow, they also present unique 
challenges; including microbial contamination, costly taste-masking requirements, chemical 
instability, expensive storage conditions and its bulkiness together with issues of freight which 
further increases cost.  
 Paediatric and geriatric populations are the most vulnerable patient group in terms of drug 
delivery and therefore, usually require special attention. The paediatric group is hugely 
heterogeneous comprising new-borns to adolescents with wide ranging physical and development 
disparities in relation to absorption, pharmacokinetics and pharmacodynamics. As the child ages, 
there are changes in organ function and metabolic capacity [3], particularly in early infancy. It is 
therefore, impossible for one formulation to fit all age sub-groups within paediatric populations, 
with medications used in paediatrics originally formulated for adults [4]. It is obvious that most 
children resist drug administration, especially oral dosage forms due to; dysphagia, nausea, 
vomiting, bad taste/odour or simply due to the fear of choking. The geriatric group on the other 
hand, comprises people aged 65 years and above. Of particular interest are those who are 75 years 
and older; as they may require greater attention during the design and medicine administration 
processes. As individuals advance in age, saliva secretion generally decreases and can result in 
greater difficulty to swallow capsules or tablets [3, 5]. Additionally, the ageing process predisposes 
patients to several health conditions, such as stroke, cancer, dementia, Parkinson’s disease, and 
gastro-oesophageal reflux disease  – and all these lead to an individual’s inability to administer 
certain oral dosage forms (tablets and capsules) [3].  
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 Essentially, many of the formulation challenges are common to both paediatric and the 
geriatric populations for either the solid or liquid oral dosage forms. In view of the aforementioned 
difficulties with respect to the use of the oral route for drug administration, regulators, industry 
and academic stakeholders have explored the development of novel oral dosage forms that assure 
acceptability and compliance to yield better therapeutic outcomes. The drug delivery innovations 
including oral thin films, that could help improve compliance in paediatric and geriatric patients 
have recently been reviewed [6]. These newer dosage forms, (for example, the fast-dissolving oral 
thin film) should offer convenience, ease of handling and administration without water, and 
guarantee quicker drug action, with little or no impact on lifestyle.  
Several research related reports exist about oral thin films for delivering various drugs, either via 
pre-gastric absorption through the buccal / sublingual mucosa or following swallowing of saliva 
dissolved drug. However, though there are many reviews related to various aspects of oral thin 
film technology, its potential applications in different patient groups and their characterization, 
they are discussed within the context of a broader range of other dosage forms such as multi-
particulates, orodispersible tablets and fixed dose combinations [130]. To the best of our 
knowledge, this is the first systematic review that addresses the specific application of oral thin 
films in two vulnerable patient groups (paediatric and geriatric). Further, it discusses in detail all 
the essential performance characteristics that are important for ensuring successful use by these 
patient groups as well as the regulatory and clinical variables that need to be considered to produce 
acceptable paediatric and geriatric formulations. 
  
2 ORAL THIN FILM TECHNOLOGY 
Oral thin films are sheets of flat films that are administered into the oral cavity. They are composed 
of very thin polymeric strips, incorporating an active pharmaceutical ingredient (API) and are 
intended to disintegrate in the oral cavity within seconds [7–9]. Water soluble polymers together 
with other ingredients are used to form the base of the film in which the active ingredient is 
incorporated. Oral thin films enhance the efficacy of drugs by dissolving within seconds in the oral 
cavity once it comes into contact with saliva and therefore do not require chewing and / or water 




 Fast dissolving oral thin films are greatly accepted by patients and caregivers for their ease 
of delivery, accuracy in dosing and portability. Oral thin films give immediate absorption and 
bioavailability because of the high blood flow and permeability of the buccal mucosa and are 
suitable and useful in paediatric, geriatric, emetic, bedridden and mentally ill patients [13]. Even 
though oral thin films generally disintegrate in seconds to minutes, they can be modified to release 
the loaded drug more slowly depending on the film thickness and polymer matrix. By the 
avoidance of dysphagia and its effective taste masking potential, fast dissolving oral thin films 
contribute enormously to improving compliance. Fast dissolving films were first commercially 
made available for systemic delivery by Novartis in 2004 (Triaminic & Theraflu Thin Strips). 
Since then, more pharmaceutical researchers have investigated its therapeutic classes and potential 
markets for local and systemic delivery of drugs. As a consequence of these efforts, novel 
applications are evolving and are being utilised by pharmaceutical companies such as Tesa-Labtec 
Ltd., Germany, which became the first company ever to be granted approval for pharmaceutical 
oral disintegrating films.  
 
2.1 Categories of oral thin films 
Currently, oral thin films come in three different forms [14] namely; 
i. Flash immediate release films 
ii. Mucoadhesive melt-away films, and 
iii. Mucoadhesive sustained release films  
Systemic or local drug treatment can be realised using all these types of oral films and a distinction 
is often made between them depending on the time of disintegration and design pattern. Oral 
patches and mucoadhesive films are available on the market as sustained release dosage forms. 
For mucoadhesive or buccal films, systemic drug therapy can be achieved primarily through 
absorption from the oral mucosa. Furthermore, oral dissolving films are placed on the tongue 
whereas mucoadhesive films are placed in the cheeks though the sublingual mucosa is also a 




2.2 General attributes of fast dissolving oral thin films 
Being a cutting-edge form of solid oral dosage forms, oral thin films possess unique attributes 
which offer significant benefits over traditional or conventional dosage forms. They are easier to 
administer and swallow without the need for water; ensure faster and better drug absorption into 
the bloodstream; combine the advantages of both solid and liquid oral dosage forms; they are more 
portable than syrups, capsules and tablets and therefore less expensive freight wise. Generally, oral 
thin films are more cost-effective than the traditional or conventional dosage forms. In addition, 
thin film drug delivery has the potential to allow for the development of sensitive drug targets that 
may otherwise not be possible in tablet or liquid formulations [10, 15]. 
 Another key attribute and advantage of these formulations is their ease of swallowing 
following hydration. Swallowability and taste (palatability) play essential roles in adherence to 
drug therapy in paediatric and geriatric patients [16]. Swallowing is a synchronised process of 
activities involving several nerves and muscles and safe swallowing is an ability developed by the 
age of twelve  years [17, 18]. Liquid formulations had been the most preferred dosage form for the 
paediatric and geriatric populations because of dysphagia [4]. However, the emergence of fast 
dissolving dosage forms, especially oral thin films with taste-masking opportunities, have provided 
a more suitable and convenient dosing alternative for patients with swallowing challenges [17]. 
 
3 MANUFACTURE OF FAST DISSOLVING ORAL THIN FILMS 
Fast dissolving oral thin films are composed fundamentally of water-soluble or hydrophilic 
polymers and the active ingredients [19]. The polymers normally constitute the physical structure 
and matrix of the film giving rise to its integrity. The chemistry behind the formulation of fast 
dissolving oral thin films depends on polymer science derived from the conventional solid 
transdermal and buccal dosage forms [20]. Taking advantage of their similarities, formulators are 
able to efficiently design unique products within a shorter development period [10]. In view of the 
flexibility in the formulation of oral thin film technology, manufacturers are able to select from a 
wide range of APIs and excipients for new product development initiatives. Material selection 
based on films’ dissolution rates and rates of absorption are taken into consideration such that an 
equivalent or an enhanced product is developed against already existing formulations such as 
tablets, liquids and capsules [21] and this provides a means of extending the patent life cycle of 
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certain drugs for pharmaceutical companies. In addition, the oral thin film technology is being 
extended to cover more complicated systems for controlled or modified release including 
applications for topical delivery [22]. 
 
3.1 Components of fast-dissolving oral thin films 
3.1.1 Active pharmaceutical ingredients  
The fast-dissolving oral thin film technology has the capacity to incorporate a variety of active 
pharmaceutical ingredients (APIs) [23]. Oral thin films can integrate most available forms of APIs, 
such as micronized (most ideal), granulated, salt and free-base forms. Low dose APIs are the best 
molecules for the development of oral thin films. Larger particle size compounds can pose some 
limitations with regards to the final film’s thickness and homogeneity, but generally size 
distributions of most drug and nutritional substances are within the classical oral thin film 
development requirements. Both soluble and poorly soluble drugs (Table 1) have been successfully 
compounded into solutions, emulsions, or dispersions that have subsequently led to the emergence 
of the oral thin film products currently available on the market [12]. Suitable drug candidates for 
fast dissolving films should be permeable through the oral mucosa, capable of taste masking, have 
a low dose and good stability in water and the pH should be close to that of the saliva [24] and 




Table 1: Oral thin films of some APIs and their solubility in water 
Drug  Solubility in water Target patient group Reference  
Piroxicam  Poorly soluble  Paediatrics and 
geriatrics 
[26] 
Tadalafil  Poorly soluble Geriatrics  [27]  
Meclizine HCl Poorly soluble Varied   [28]  
Quinapril HCl Freely soluble Varied  [29] 
Ketoconazole  Poorly soluble  Varied  [30]  
Furosemide  Poorly soluble Varied  [31] 
Sildenafil citrate  Slightly soluble Geriatrics  [32, 33] 
Granisetron HCl Freely soluble  Varied  [34] 
Glibenclamide  Poorly soluble  Geriatrics  [35] 
Chlorpheniramine Maleate Freely soluble Paediatric  [36, 37] 
Cetirizine HCl Freely soluble Varied  [38, 39] 
Selegiline Freely Soluble  Parkinson’s  [40] 
Varsatan  Poorly soluble Geriatrics  [41] 
Loratadine  Poorly soluble Geriatrics  [42] 
Dexamethasone  Poorly soluble  Varied  [43, 44] 
Tetrabenazine  Poorly soluble  Paediatrics  [45] 
Carvedilol  Poorly soluble Varied  [46] 
Allopurinol Poorly soluble Varied  [47] 
Omeprazole  Very slightly soluble Paediatrics [48, 49] 
Clobazam Slightly  Paediatrics  [50] 
Ondansetron HCl Poorly soluble  Paediatrics  [22, 51] 
Rizatriptan benzoate  Soluble  Varied  [52] 
Montelukast Sodium soluble Varied  [53] 
 
Formulators can choose to develop multiple formulae to obtain manifold strengths for a specific 
API, or produce a single formula that is cut into multiple strengths based on the size of the unit 
area [10, 12]. As a result, a film of 10 mg strength can be reduced to 5 mg by dividing the unit size 
without further formulation efforts. 
 
3.1.2 Film forming polymers  
Water-soluble polymers are used to form the matrix of oral thin films and can be used individually 
or in combination depending on the desired properties of the film [12, 54]. The toughness is related 
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to the kind of polymer and its quantity within the formulation. The type of polymer also defines 
the disintegration and dissolution profile of the film as well as the other mechanical attributes, such 
as tensile strength, folding endurance and degree of elongation [43, 55].  
Some of the polymers commonly used for formulating oral thin films include pullulan, 
polyvinyl alcohol (PVA), hydroxyl-propyl-methyl cellulose (HPMC), carboxymethyl cellulose, 
hydroxyl-propyl cellulose, sodium alginate, starch, xanthan gum and guar gum [12, 15]. In view 
of the vital role polymers play in the development of oral thin films, they comprise at least forty-
five percent (45% w/w) of the entire film [56].  
 
3.1.2.1 Polymer toxicity (safety) 
As noted previously, the paediatric and geriatric patients are more vulnerable (in terms of 
normal pharmacokinetics and pharmacodynamics), than the general adult population, Further, 
most dosage forms administered to these populations are not specifically tailored to their unique 
requirements. Therefore, the safety of the dose of drug as well as the type of excipients used is of 
paramount importance. The polymers used must be non-toxic, non-irritant and must not contain 
leachable impurities. In general, most of the polymers employed are safe and in most cases already 
approved for use in the food, drug and cosmetic industries, and therefore are generally regarded as 
safe (GRAS). The polymers used can be classed into natural such as pullulan, pectin, carrageenan 
and synthetic such as Carbopol, cross carmellose sodium and PVA depending on need and 
availability [11, 57, 58]. Khan and co-workers tested the cytotoxicity of Metolose (HPMC) based 
films containing omeprazole for buccal delivery to paediatric patients using MTT assay and 
showed to be safe for use in children [49].  
The application of certain polymers imparts specific properties to the final formulation. For 
example, gelatines come in different molecular weights which can impart aesthetic and glossy 
features to films [54, 59]. Pullulan is also regularly employed to produce films with good 
solubility, mechanical strength and stability at varied temperatures [54]. In the formulation of 
triclosan, different grades of HPMC (Methocel E3, Methocel E5 and Methocel E15 premium LV) 
were used as polymers and the result showed that Methocel E5 at 2.2%w/v yielded films with 
excellent properties. In addition, granisetron hydrochloride was developed using HPMC and 
pullulan and the outcome demonstrated the importance of increasing polymer concentration on 
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physical and mechanical properties. Films from pullulan at 40 – 45% did not exhibit good 
mechanical strength while HPMC at a concentration of 40% formed a film that was difficult to 
remove. However, the film stickiness became better when the HPMC concentrations were 
increased above 50% [34]. 
Even though polymers are commonly used excipients, they have emerged as vital 
components in the development and formulation of fast dissolving oral thin films. Therefore, a 
fundamental knowledge and understanding of the properties – chemistry, rheology, and physico-
chemical behaviour of polymers is essential to successfully develop effective oral thin films. It is 
crucial to choose the appropriate polymer that will produce thin films with properties that will 
assure therapeutic success [60]. 
 
3.1.3 Plasticizers 
Generally, plasticizers influence the mechanical properties, such as tensile strength, elastic 
modulus and percent elongation of oral thin films and therefore, its choice and amount should be 
properly taken into consideration [60]. They are vital to obtaining the desired film flexibility [61] 
and act by lowering the glass transition temperature of the films resulting in improved film 
plasticity and elasticity [62]. Some of the commonly used plasticizers include polyethylene glycol, 
propylene glycol, glycerol, sorbitol (also a sweetener), phthalates, low-molecular-weight 
macrogols, and citrates [7]. Water is still present in the dried films and can act as a plasticizer in 
synergy with any of the plasticizers mentioned above. Plasticizers at high concentrations may 
cause impairment of moisture resistance giving rise to tacky films or stability challenges. Drug 
solubility and absorption can also be affected by the addition of plasticizers [7, 63] and therefore 
the concentration of plasticizer relative to the polymer content needs to be optimised.  
 
3.1.4 Surfactants  
Surfactants (or surface active agents) are micro-molecules which adsorb at surfaces and lower the 
interfacial tension. Surfactants work as wetting or solubilizing agents in oral thin films and help in 
ensuring that the films disintegrate within seconds to release the API [64, 65]. Commonly used 
surfactants in thin film formulations include poloxamer, sodium dodecyl sulphate, benzalkonium 




3.1.5 Saliva stimulating agents 
Films are intended for fast disintegration in the mouth and mainly dependent on the presence and 
quantity of saliva. It is therefore vital to introduce saliva stimulating agents in the formulation of 
fast dissolving oral thin films to increase saliva production rates [67]. Acids used in the food 
industry are commonly utilised as saliva stimulating agents and these include citric (most 
preferred), lactic, ascorbic, malic and tartaric acids [9, 68]. Saliva stimulants are used alone or 
combined to achieve the desired effect and these typically form about 2 – 6% w/w of the entire 
oral film. 
 
3.1.6 Colouring agents  
A full range of natural colouring agents and juice concentrates are approved and available for 
incorporation in the formulation of oral thin films [54]. These include FD & C natural colouring 
agents and pigments such as silicon, zinc and titanium dioxides. The concentration of colouring 
agents in oral thin films do not exceed 1% w/w [9]. 
 
3.1.7 Taste masking (sweetening and flavouring) agents  
Many drugs are bitter in their natural form and even drugs that are only partially soluble in saliva 
are accessed by the taste buds. Therefore, it is essential for taste-masking agents to be incorporated 
into fast dissolving films. Depending on the physical state of the drug in the film and its solubility 
profile in saliva, various taste-masking techniques are available for application [69].  
 Taste masking additives include sweeteners and flavours that are capable of disguising the 
unpleasant taste of drugs [70, 71]. Using a combination of sweeteners and flavours to overcome 
an unpleasant taste is the most common approach in taste masking [72]. Other more sophisticated 
methods such as particle coating, and complexation with ion exchange resins are used. Several 
sweetening agents exist in both natural and synthetic forms and typical sweeteners include 
fructose, glucose, maltose, galactose, sucrose, dextrose, isomaltose, xylose and ribose [55]. Others 
are mannitol, aspartame, sucralose, neotame, sodium saccharin, acesulfame-K, xylitol, and 
sorbitol. Some sweeteners are sweeter than others; for example, fructose is sweeter than sorbitol 
and mannitol; acesulfame-K and sucralose have respective sweetness values of more than 200 and 
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600 times that of fructose. Others such as mannitol and xylitol provide good mouthfeel and cooling 
sensations in the mouth [34]. First generation artificial sweeteners are saccharin, cyclamate and 
aspartame, whiles acesulfame-K, sucralose, alitame and neotame are the second generation of 
synthetic sweeteners. Typically, different combinations of sweeteners and flavours are employed 
to achieve the desired taste-masking effect. For example, citric acid and passion fruit flavour were 
found to be suitable for complete taste-masking of cetirizine HCl [39].  
Flavours help to improve the acceptance of drug formulations by attempting to conceal 
unpleasant smell. Therefore, both natural and synthetic flavours are employed to mask such APIs 
and improve the organoleptic indices of oral thin films. The acceptance of flavours is affected by 
ethnicity and the age of the patients. Paediatric patients like fruity flavours e.g. raspberry and 
punch, whiles geriatric patients tend to prefer mint flavours e.g. orange [54]. Importantly, the 
amount of flavour that can be incorporated depends on the API, the flavour type and its strength. 
Generally, about 10% w/w concentrations of flavours are added to formulate fast dissolving thin 
films. Examples include the synthetic categories (oleoresins, peppermint oils, cinnamon oils and 
spearmint oils) and fruity flavours (vanilla, cocoa, coffee, mango, chocolate and fruit essences 
such as cherry, raspberry, apple and pineapple among others). These flavours can be used 
individually or in combination [19, 59, 73]. 
 
3.1.8 Permeation enhancers (for mucoadhesive films) 
Though fast dissolving oral thin films are typically placed on the tongue for rapid dissolution and 
swallowing, multipurpose oral thin films are increasingly being employed for initial buccal 
absorption and subsequent dissolution and eventual swallowing of the remaining free flowing gels, 
containing unabsorbed drug. A typical example is NiQuitin oral thin films for nicotine replacement 
therapy to aid smoking cessation [74]. This therefore requires use of permeation enhancers to 
improve the initial absorption of drugs into the systemic circulation [58]. Permeation enhancers 
are added to increase the permeation of the drug molecule across the membrane, thereby aiding 
buccal and sublingual absorption [20]. Commonly used permeation enhancers are dextran 
sulphate, cyclodextrin, menthol, sodium deoxycholate, aprotinin, benzalkonium chloride, lauric 
acid and oleic acid [75]. It has also been proposed that permeation enhancers improve mucosal 
transport via changing the mucus rheology by reducing the viscosity of the mucus layer, 
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modification of drug solubility parameters and facilitating transport by way of increasing the 
membrane fluidity [76, 77]. 
 
3.1.9 Thickening agents 
Film stabilizers and thickening agents are incorporated to enhance the viscosity and uniformity of 
the solution or suspension prior to casting [54]. For example, in the development of oral polymer 
films containing loperamide, Woertz and co-workers demonstrated that the content uniformity 
increased when thickening agents were added [78]. Non-artificial gums such as xanthan, guar and 
locust bean gums, carrageenan and cellulosic derivatives can be used at concentrations of up to 
5% w/w. Other additives such as suspending and emulsifying agents may also be added in small 
quantities to enhance the properties of the films [79]. 
 
3.2 Patient-centred considerations for formulation of fast dissolving oral thin films  
3.2.1 Acceptance 
Dosage form acceptance by patients is essential to its compliance. Problems usually encountered 
in the use of conventional dosage forms such as dysphagia can be overcome by oromucosal 
formulations [80]. Though crushing of traditional oral dosage forms to make it easier to swallow 
could help, it may affect performance indicators such as dissolution and absorption rates of the 
drug [81]. Though orodispersible tablets can also improve swallowing in dysphagia, issues of 
aspiration still persist [18]. The use of liquid formulations to ease swallowing problems is fraught 
with challenges including dosing inaccuracy, drug instability and unpalatability. With the 
advantage of a fixed dose and ease of administration without water, adequately formulated oral 
thin films can address all the problems of other oral dosage forms leading to high levels of 
acceptability.  
In an acceptability study with 19 patients, dexamethasone oral thin film showed superiority 
in terms of taste and ease of administration compared to a tablet [43]. Therefore, in the formulation 
of oral thin films, it is imperative to consider as essential, acceptance issues such as taste, 
mouthfeel and mucosal irritability; which may appear less important for capsules, tablets or 
liquids. However, it is important to note that a dosage form that is ‘too acceptable’ could be 
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susceptible to drug misuse, especially in paediatric populations and must be strictly kept away 
from the reach of children [80]. 
 
3.2.2 Excipients  
Practically, most of the excipients used in the formulation of fast dissolving oral thin films have 
been used in one dosage form or the other either as polymer matrices or coating materials. These 
excipients have to be evaluated for the quantity required, in view of age appropriateness and 
acceptable daily intake [4]. Residual solvent assessment is necessary if organic solvents are used 
in the development of oral thin films by solvent casting. This is because organic solvents are 
hazardous and therefore, should not exceed the daily acceptable intake and this is usually specified 
in standard regulatory quality documents such as United States and British Pharmacopoeias [13, 
82].  
On regulatory requirements, it is essential to justify the use of an excipient in the 
formulation, especially if the product is meant to be delivered to the paediatric population [83]. As 
a result, the European Medicines Agency (EMA) recommends in its guidelines, specific 
requirements for the development of medicinal products for children, pointing out the need for 
safety data on the excipients used [84]. It is therefore prudent to incorporate excipients that have 
been tested and approved for use in other dosage forms to shorten the development and safety 
evaluation processes. However, according to Pries and co-workers, approaches with new 
substances, such as those able to mask bitter taste appear hopeful but may increase the regulatory 
requirements [85]. 
 
3.2.3 Appearance  
The appearance of a dosage form including oral thin films is vital to achieving compliance by 
patients [86]. Even though the appearance of oral thin films may differ, they should generally be 
smooth, soft, flexible and free of air bubbles [81]. However, dosage forms in which the colour is 
associated with sweetness are capable of drug misuse, particularly in children and therefore 
requires caution, with appropriate labelling and storage. By using different polymers, it is possible 
to improve the appearance of oral thin films as well as prevent the recrystallization of APIs during 
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storage to maintain the physical aesthetics and visual appeal of the dosage form. Polymers such as 
HPMC, polyvinyl pyrrolidone and methylcellulose are known recrystallization inhibitors [23].  
  
3.2.4 Taste and palatability  
Taste plays an important role in the acceptability of a dosage form, and since oral thin films are 
intended to disintegrate in the mouth, there would be an unavoidable interaction with the taste 
receptors [19]. Dosage forms and or APIs with unpleasant taste may lead to non-compliance by 
the patients [4, 87] and therefore an effective approach to mask the unpleasant taste is necessary. 
Probably, the cheapest approach to mask the bitter taste of APIs is the incorporation of flavours, 
sugar alcohols and artificial or nutritive sweeteners; or a combination of these excipients [88]. 
Several attempts have been made to mask the bitter taste of some drugs as reported in the literature. 
For instance, an oral thin film containing cetirizine hydrochloride was deemed to have masked the 
bitterness of the API by the application of sweeteners and other taste masking agents [38, 39]. 
Taste-masking evaluation is carried out to determine the efficiency of the chosen approach. Human 
taste panels and electronic tongues are employed depending on the availability and suitability, to 
appraise the palatability of various developed formulations including oral thin films [55].  
 
3.2.5 Mouthfeel 
Unlike the conventional solid oral dosage forms in which ingestion is critical, oral thin films, 
disintegrate in the mouth and remain there for a relatively longer period. As a result, texture and 
mouthfeel, as well as size considerations, have to be provided for in the development of oral thin 
or fast dissolving films [81]. The relatively small space of the oral cavity available for drug 
application limits the size of oral thin films. Reported studies adjudged formulations with film area 
of 4 cm2 and a thickness of 0.10 mm [59] as well as 6 cm2 and thickness of 0.35 mm [89] as being 
acceptable for oral application. On the other hand, film with areas of 1 cm2 and 2 cm2 were 
evaluated as acceptable for mucoadhesive films [90]. A major difference between mucoadhesive 
and fast dissolving films lies in their behaviour in the mouth, and hence the texture has to be 
estimated. For fast dissolving films, the texture following disintegration needs consideration since 
remnant particles may negatively affect the mouthfeel and its resultant influence on the 
acceptability of the films. An unpleasant mouthfeel may be inevitable if the film is gummy after 
16 
 
wetting; because of viscous polymer behaviour [81]. Excipients such as polyacrylic alcohols 
(PAA) are capable of improving mouthfeel due to their cooling effect [66]. In the case of 
mucoadhesive films, texture following disintegration is less important and features of functional 
importance include adhesiveness, flexibility, and change in the residence time within the oral 
cavity [90]. 
 
4 METHODS OF MANUFACTURING FAST DISSOLVING ORAL THIN FILMS 
Methods used in the development of fast dissolving films include solvent casting, hot melt 
extrusion (HME), semisolid casting, solid dispersion extrusion and rolling [81, 90]. These methods 
can be used individually or in combination, but solvent casting and HME are the most commonly 
employed methods [85]. 
 
4.1 Solvent casting 
Solving casting is the most widely used method for the manufacture of fast dissolving oral thin 
films [66]. Hydrophilic polymers together with other water-soluble ingredients are used as film 
formers. The solvent chosen is usually on the basis of the solubility of the API. The film-forming 
polymers are usually dissolved in a solvent, either in water only or in combinations of water and 
organic solvents and the other excipients are then added to form a homogenous solution [20]. 
Several papers have been published in which solvent casting was used to obtain films for paediatric 
or geriatric applications. For example, Mahmood and co-workers [36], and Teja and co-workers 
[37] successfully formulated chlorpheniramine maleate oral thin film for paediatric application to 
aid swallowability as well as improve therapeutic effectiveness using the solvent casting method. 
Bonsu and colleagues reported the application of solvent casting to develop diclofenac sodium oral 
thin film for the treatment of osteoarthritis in older adults [91]. Similarly, furosemide oral thin film 
aimed at improving the solubility of the API was formulated using solvent casting [31].  
Organic solvents are capable of improving the solubility of the API and reducing the drying 
time. Once the polymer matrix is formed, the API is added, typically pre-dissolved or pre-dispersed 
in an aqueous medium. Removal of any entrapped air bubbles is mandatory before casting is done; 
as this is essential to obtaining uniformity of film properties [66]. Specific types of equipment such 
as rollers (Figure 1) are required for pouring the solution on an inert base and the space between 
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the roller and the substrate determines the required thickness of the film. Once the casting is 
undertaken on a suitable platform (substrate), it is allowed to dry, preferably in hot aired oven or 
by convection [92]. When sufficient dryness is achieved, the film is gently removed or peeled off 
and cut into suitable sizes and shapes with respect to the intended dosage of the API. Although in 
industry, the films are sometimes rolled (known as “roll stock”) and stored, until a later date before 
cutting, it is really ideal to cut and package it soon after preparation to maintain its stability and 
integrity. The packaging materials of thin films are meant to render adequate mechanical strength 
to protect the film against humidity and temperature [4]. In view of the film characteristics, single 
unit or multi-unit dispensers are chosen. 
 
Figure 1: Equipment for the commercial processing of oral thin films by solvent casting 
(Reproduced from Amin et al [61] under Creative Commons Attribution 4.0 International 
License). 
 
4.1.1 Advantages of solvent casting 
There are several benefits associated with films produced by a solvent casting method. Solvent 
casting is ideal for the development of oral thin films incorporating heat-sensitive APIs. This is 
because the temperature required to achieve dryness is relatively low in comparison to those of 
HME [10, 93]. In addition, oral thin films produced by solvent casting have better physical 
properties, excellent homogeneity of thickness and weight, as well as easy and low cost of 
manufacture and processing [61]. 
 
4.1.2 Disadvantages of solvent casting 
In spite of the usefulness of solvent casting for producing oral thin films, it is associated with some 
limitations. Solvent cast films may contain traces of residual solvents which are mostly organic in 
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nature and can be hazardous to patients and the environment and for this reason, many countries 
have adopted regulations governing the use of organic solvents [10, 18]. The manufacture of oral 
films on a large scale is problematic, as heating, temperature and mixing rates could introduce 
variability in the uniformity and quality of the final films [93]. It would require a huge investment 
to optimise the production units such as mixing rates, drying time and film thickness and this may 
affect the scale of commercial production [20]. Films developed by solvent casting are liable to 
brittleness upon storage shown by reduction in percent elongation as a result of evaporation of the 
residual water over time. 
 
4.2 Hot melt extrusion (HME) 
HME is an innovative drug delivery technology that has received intense attention from both the 
pharmaceutical industry and the academic research community [94, 95]. HME was first made 
available in the plastics industry and in its elementary form, it compacts, blends, grinds and kneads 
powder or solid mixtures into uniform products for further processing into different formulations 
(Figure 2). 
 
Figure 2: The hot melt extrusion process 
 
Hot melt extrusion is a solvent-free process which involves the use of heat to form the films unlike 
in the solvent casting method. The excipients and the API are heated and homogenised by a screw 
extruder until they are fully blended. The blend is passed through a flat extrusion die which presses 
the extrudate into the desired film shape, cooled and cut to the required size and packaged [96]. 
extruding the matrix 
blend through the die
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The main components of the HME equipment are the hopper, extruder, film die and the roller. The 
extruder also has one or two rotating screws in a static cylinder barrel as shown in Figure 3. 
 
Figure 3: Hot melt extrusion equipment (Reproduced with permission) [129] 
 
HME is a versatile method that has achieved considerable success in academic research and the 
pharmaceutical industry for its role in drug delivery via oral, transdermal and transmucosal routes 
in the form of tablets, films, capsules, implants, granules and pellets. It is also effective for the 
masking of the unpleasant taste of pharmaceutical ingredients thereby improving compliance [97, 
98]. In a study to evaluate the in vivo and in vitro taste masking efficiency of hot melt extruded 
paracetamol formulations, a panel of six healthy volunteers appraised the formulations to be 
effective and the rating was consistent with the electronic tongue results of the same formulations 
[99]. Similarly, fast dissolving chlorpheniramine maleate films were developed by HME and the 
results of the taste masking demonstrated that the method used had reduced the bitterness of the 
drug in the film relative to the pure drug and physical mixtures [100]. In another study, 
Manirruzaman and co-workers designed oral thin films of ketoconazole produced by HME which 




4.2.1 Advantages of HME 
HME has several unique advantages over other manufacturing techniques for producing orally 
administered solid dosage forms [94, 96, 101, 102]. There are fewer processing steps and therefore 
produces films and other formulations quickly, which saves time. It is an anhydrous and solvent 
free process and therefore does not require water or other solvents, and hence eliminates problems 
associated with drug instability as well as issues of residual solvents. It is also proven to be 
environmentally friendly because of the avoidance of organic solvents. There is a homogeneous 
dispersion of fine particles in view of the agitated mixing and films produced by HME therefore 
have the potential of improving the solubility of poorly soluble drugs.  
 
4.2.2 Disadvantages of HME 
The major drawback of HME is the negative impact of the high temperatures (thermal degradation) 
on APIs and other ingredients, especially those which are thermo labile [63]. All the ingredients 
used in HME must be free from water or other solvents; otherwise, the heat applied during 
processing can cause it to boil and evaporate thereby creating voids in the final film product which 
can affect its uniformity, appearance and strength. The rheology of the polymers is essential to the 
processing of the films by HME, therefore the number of polymers that can be easily processed is 
limited [95, 96, 101]. 
 
5 REGULATORY REQUIREMENTS OF FAST DISSOLVING ORAL THIN FILMS 
Pharmacopoeias such as Ph. Eur., USP, and BP, provide monographs of common dosage forms. 
Dosage forms administered orally such as orodispersible tablets, medicated chewing gums, oro-
mucosal preparations, and lyophilisates are included but monographs and specifications for oral 
thin films of various dissolution profiles are yet to be established [103]. In addition, there are 
inadequacies in the pharmaceutical technical procedures for analysis and quality control of oral 
films. For example, though the disintegration and dissolution analytical procedures may be 
available, the recommended conditions such as volumes of dissolution media do not reflect the 
natural conditions in the oral cavity [103]. Although the EMA and FDA have recently provided 
guidelines for industry, especially in development of formulations for vulnerable patient groups 
such as paediatric and geriatric populations, more research is required to establish global standards 
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since most of the reported studies vary greatly in the methodology and approaches, and it is 
difficult to tell which is appropriate. 
 
5.1 Characterisation and quality control of fast dissolving oral thin films 
In view of the novelty of fast dissolving films, it is expected that these films would be flexible, 
soft, elastic, palatable as well as physico-chemically stable. Therefore, several quality control 
attributes are usually evaluated. Some of these parameters are considered carefully in the design 
and development stages of the oral thin films and are thus, not tested at the end of manufacturing 
process. Characterisation of fast dissolving oral thin films is a fundamental undertaking and 
includes the assessment of parameters such as in vitro formulation disintegration and drug 
dissolution, uniformity of weight and thickness, folding endurance, tensile (mechanical) strength, 
, percent elongation, Young’s modulus, moisture content, assay of drug content and swelling 
properties among others [104]. The following are some of the various essential quality attributes 
that define optimised oral thin films. 
 
5.1.1 Surface pH 
Irritation may occur in the oral mucosa if the film is too acidic and therefore it is necessary to 
determine the surface pH of the films. Because it is intended to disintegrate in the mouth the pH 
of the films should be close to the pH of saliva, neutral pH values or values close to 7 are ideal 
[22]. The films are made to hydrate in small volumes of water, simulating absorption of saliva and 
the pH values are recorded using a pH meter [56]. The surface pH of the films can also be estimated 
by using pH paper. The film is placed on 1.5% w/v of agar gel, allowed to hydrate and the pH 
paper is then brought into contact with the swollen film and any colour change is noted and 
interpreted appropriately [56, 105]. 
 
5.1.2 In-vitro disintegration 
Oral thin films are designed to disintegrate in the mouth and disintegration tests are therefore 
performed to determine the time taken for a film to split or break up when it comes into contact 
with saliva or dissolution medium. Assessment of disintegration is usually based on visual 
inspection where the film is placed in water (25 ml) or any appropriate medium and monitored 
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until it breaks into pieces. The United States Pharmacopoeia (USP) disintegration apparatus can 
also be used to study the disintegration time. The ideal disintegration time for fast dissolving oral 
thin films is between 5 – 30 seconds [9, 54], though disintegration within 60 seconds is acceptable. 
Disintegration has been modelled using various approaches including measuring contact angle and 
analysing swelling behaviour of the oral thin films. In addition, other approaches including slide 
frame the Petri dish protocols have been reported and these tests deal use a small volume of 
disintegration medium simulating the small volume of saliva in the mouth. Mishra and Amin 
placed films on a stainless steel wire mesh containing 10 ml of distilled water and the disintegration 
time was recorded as the time taken till the film broke [38, 39]. In another test, disintegration was 
evaluated in a glass dish with 25 ml distilled water. The dish was swirled intermittently and the 
time taken for the film to start breaking recorded. Hydration of films was measured in a diffusion 
apparatus [106]. Although the above approaches can allow the distinguishing of different oral thin 
films they do not sufficiently mimic the physiological conditions in the oral cavity, since the 
mastication action of the tongue on the oral thin films is not accurately replicated. Mostly, distilled 
water is used as the disintegration medium and there is no simulated saliva described in the various 
Pharmacopoeia, though some researchers have reported disintegration using simulated saliva [49]. 
 
5.1.3 Swelling index 
Polymers used for developing oral thin films are hydrophilic and therefore, it is necessary to study 
their swelling behaviour [107]. This is however, more applicable for swelling controlled release 
bioadhesive systems, compared to rapid release systems which are meant to disintegrate or 
dissolve very quickly within a few minutes. Swelling of polymeric films is a fundamental function 
of bioadhesion [108] and the extent and rate of swelling are also essential in controlling how much 
of the drug is released [106, 109]. Hydrophilic polymers with dissimilar structures possess varying 
degrees of swelling based on the relative resistance of the matrix network structure to the 
movement of water molecules. For example, a polymer chain with low ability to form hydrogen 
bonds is incapable of forming a strong network structure, and water penetration is difficult to occur 
[59]. Once the number of hydrogen bonds, as well as the strength of the polymers, increase, the 
diffusion of water molecules into the hydrated matrix occurs at a slow rate [110]. Panomsuk [111] 
discovered that the introduction of mannitol into methylcellulose films decreased the swelling 
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index of the resulting matrix which may have resulted from hydrogen bonding between the drugs 
and polymeric matrix.  
 Swelling index studies are estimated using various simulated fluids; where the sample is 
usually weighed and placed in a previously determined stainless steel wire mesh or sieve [112]. 
The wire meshes together with film are then submerged into a sufficient volume (ideally 20 ml or 
more) of the simulated fluid in a beaker. The excess water on the surface of the film is removed 
by the aid of a filter paper prior to reweighing. The increase in the film weight is determined at 
regular time intervals until a constant weight is obtained. Mathematically, the degree of increase 
or swelling is calculated using the equation below: 
 





where; Wt is weight of film at time = t, and Wo is weight of the film at time 0. It can be expressed 
as a percentage. 
 
5.1.4 In-vitro dissolution 
There are various means of determining the dissolution of fast dissolving oral thin films. 
Commonly, the USP dissolution apparatus is used with various modifications as is practically 
possible. Individual films are used in the dissolution test and an aliquot is withdrawn periodically, 
suitably timed and the dissolution medium is replaced accordingly [51, 54, 113]. The solutions 
obtained are analysed using UV spectrophotometer or HPLC at specific wavelengths. Further, the 
basket or paddle method specified in any of the pharmacopoeias can be adopted. However, it can 
be difficult using the paddle method for fast dissolving oral films dissolution test because the films 
are more likely to float on the surface of the dissolution media.  
 
5.1.5 Thickness  
Uniformity of thickness is essential to obtaining accuracy of a dose of oral thin films. A film that 
has suitable thickness assures the comfort of administration and the acceptable thickness of typical 
oral thin films is typically 50 - 1000µm. The film thickness is commonly measured with a 
micrometre screw gauge, Vernier callipers or scanning electron microscopy images [15, 114] and 
normally measured at 4 different locations of the films and the mean value estimated [59, 107]. 
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5.1.6 Moisture content 
The moisture content has a critical effect on the mechanical strength, adhesiveness, and friability 
of films [115]. Many factors account for the high amount of moisture, including; hygroscopic 
properties of API, polymers, plasticizers, solvent system used to dissolve the polymeric mixture, 
and manufacturing techniques. In general, the moisture content of the film is determined by 
methods such as Karl Fischer titration or thermogravimetric analysis (TGA) [13]. In TGA, pre-
weighed films are heated to temperatures of 100 – 120 °C until they attain constant weight. The 
relation below is then applied in estimating the amount of moisture in the film, expressed as a 
percentage [59]. 
 





5.1.7 Uniformity of weight 
When the films are dried, removed and cut into desirable sizes, the weight of individual films is 
estimated. The manufacturing method is effective if the weight variation is low as this would 
indicate uniformity of content [116]. Fundamentally, the weight variation is estimated to ensure 
that the films comply with uniformity of content of the API and thereby ensuring accuracy in 
dosing [12, 20].  
 
5.1.8 Surface morphology 
Scanning electron microscopy is an essential tool with a variety of applications. It is used to obtain 
morphological, topographical and compositional information of solid materials and can also detect 
and analyse surface structures, examine surface contaminations, obtain information in 
microstructures, and reveal spatial variations in chemical substances [48, 106, 117]. It is also used 
to obtain images of oral films displaying the various units in the films and as a result, the spatial 




5.1.9 Mechanical Properties 
Tensile strength 
Generally, the mechanical strength is characterised by its tensile strength, which is related to the 
stretching ability of the film [54, 91]. The mechanical strength is measured by instruments such as 
texture analyser or Instron tensile tester, in which the film is held between two clamps and pulled 
to determine the tensile strength by noting the force or stress at which it breaks into two parts. 
Tensile strength is then, determined by the formula; σTS = 
𝐹𝑚𝑎𝑥
𝑨
 ; where: σTS is the tensile 
strength, Fmax is the load (force) at break and A is the initial cross-sectional area [105]. 
Folding endurance  
This is evaluated by folding the film at the same place repeatedly at an angle of 180° until the film 
breaks [55, 103] and is an indirect measure of flexibility. The number of times the film is folded 
till the breakage is the folding endurance [119]. It is important for oral thin films to have a good 
folding endurance in order to maintain the dose integrity. Films with folding endurance value of 
300 or more is considered to be ideal [120]. 
Young’s Modulus  
Young’s modulus refers to the elasticity or stiffness of the oral thin films. It is the resistance to 
deformation of the films and can be estimated by plotting stress and strain curve, where the slope 
represents the modulus [67] and the greater the slope, the better the tensile modulus and 
deformation and vice versa [95]. A film that shows higher tensile strength and greater Young’s 
modulus is hard and brittle with small elongation. 
Young’s modulus = 
𝐬𝐥𝐨𝐩𝐞 𝐱 𝟏𝟎𝟎
𝐟𝐢𝐥𝐦 𝐭𝐡𝐢𝐜𝐤𝐧𝐞𝐬𝐬 𝐱 𝐜𝐫𝐨𝐬𝐬−𝐡𝐞𝐚𝐝𝐬𝐩𝐞𝐞𝐝
 
 
Percent elongation (elongation at break) 
Elongation is a deformation, characteristically, a change in shape of an object when stress is 
applied and is measured to obtain a predictive value of ductility of the polymers used. Percent 
elongation shows the stretching ability of the material without breaking whiles elongation at break 
indicates the point at which the film can be stretched when is broken by the applied stress [64]. All 
kinds of elastomers exhibit the elastic elongation phenomenon. When stress is applied to a sample, 
the strain is generated, and the sample elongations will become more predominant as the amount 
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of stress applied increases [56]. Upon reaching a certain limit, the sample breaks; this point of 
breakage is referred to as percent elongation break. The relation below can be used for estimating 
percent elongation [54]. 
 
% elongation = 
𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐥𝐞𝐧𝐠𝐭𝐡 𝐨𝐟 𝐟𝐢𝐥𝐦 𝐱 𝟏𝟎𝟎
𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐥𝐞𝐧𝐠𝐭𝐡 𝐨𝐟 𝐟𝐢𝐥𝐦
 
 
5.1.10 Assessment of taste masking efficiency and organoleptic indices  
Taste and palatability play important roles in the acceptability of medicines by patients [121, 122]. 
Therefore, taste is a critical feature of oral thin films and taste masking is essential for unpleasant 
or bitter drugs to enhance patient compliance, especially in the geriatric and paediatric populations 
[123]. Various means of assessing taste-masking efficiencies are available. The use of taste panel 
is an option where human volunteers evaluate the organoleptic indices of the films and values are 
recorded in levels of acceptability [5, 72]. There are arguments of lack of objectivity in using 
human taste panels [81] especially for formulations meant for paediatric use; based on the principle 
that taste preference is age and ethnicity dependent [5]. However, though the human taste panel 
has limitations, it is the only realistic means by which levels of acceptability of grittiness and good 
mouth-feel can be assessed and therefore very difficult to entirely eliminate from the essential 
quality assessments [87].  
 There is also innovative in vitro approaches in which taste is assessed electronically, using 
the electronic tongue [121]. For example, commercially available electronic taste system by Insent 
(Astugi-Shi, Japan) and AlphaMos (Toulouse, France) determine human taste attributes such as 
sweetness, saltiness, bitterness, sourness and astringency [124]. The measurement principle is 
based on its sensitivity to different ionic molecules. Together with the ability of the sensors to bind 
or interact with different chemical structures, they allow an estimation of the overall impression 
rather than only the determination of the concentration of the API [99].  
 
5.1.11 Pharmacokinetic profile 
Oral thin films generally employ water soluble polymers which allows the dosage form to be 
quickly hydrated by saliva, adhere to the mucosa, and disintegrate within a few seconds, dissolve 
and release the API for mucosal absorption when placed on the tongue or in the oral cavity. The 
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sublingual mucosa having a thin membrane and large veins is readily permeable, which gives 
instantaneous bioavailability of drugs due to rapid blood flow [54]. Pre-gastric absorption can also 
improve bioavailability by bypassing the hepatic first-pass effect with consequent reduction of 
dosage and unwanted effects [11].  
Though oral thin films are effective formulations for oral drug delivery, they have certain 
limitations including poor ability to load drug and dependence of the drug release physico-
chemical characteristics of the target drug, for example its aqueous solubility. As a result, 
controlling the rate of drug release from oral thin films is difficult, though can be achieved through 
modification of the polymer matrix [51, 113]. Consequently, oral thin films are appropriate as 
single dose immediate release products. Therefore, the plasma pharmacokinetics, relative 
bioavailability and safety profile of the drugs in oral thin films need to be established as superior 
alternative to the traditional tablets and capsules [60]. This is primarily achieved by comparing the 
in vivo rate (peak plasma concentration; Cmax) and extent (area under the curve [AUC] from 
administration to last observed concentration time; AUC0–t) of drug absorption after single-dose 
administration of the test and reference drugs in human volunteers [2, 32, 125]. 
 
6 PACKAGING AND STORAGE OF FAST DISSOLVING ORAL THIN FILMS 
Oral thin films are moisture sensitive and therefore require special packaging techniques 
which are essential to provide mechanical protection and maintain the stability of the films. 
The packaging materials act as barriers to the penetration of moisture, air (oxygen) and light. 
Packaging is also important to ensure easy handling and transport from one place to another. 
Aluminium foils are regularly used in the packaging of thin films as these are considered to 
be the most ideal for maintaining the integrity of the films [19]. Lidding foils are also reported 
to be used for the packaging, especially if tamper proof is required. The packaging of oral thin 
films has usually been done in single unit dosage formats that contain one or two films for each 
pouch and enables portability of the product [12]. It also allows for multiple-count options to 
accommodate dispensing needs and regional requirements. Films are made available in both 
single and multi-unit dose blisters; though single dose packaging is often preferred to avoid 
accidental overdosing should the films stick together. Once the films are packaged it is 
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thoroughly examined before placing into the secondary container. PocketpaksTM for cool mint 
Listerine has been introduced by Pfizer [10, 59], while a patented packaging system - Rapid 
card for Rapid® films (APR-Labtec GmbH) [14, 125], which has the same size as a credit 
card with three films on each side, is individually removable. 
 
7 COMMERCIAL FAST DISSOLVING FILM TECHNOLOGIES 
7.1 SoluleavesTM 
Soluleaves™ [5, 54, 81], films are designed to dissolve fast once in contact with saliva, releasing 
the active ingredients and flavours quickly. The delivery system can be used for a wide range of 
therapeutic areas and nutritional products. This method is particularly useful for paediatric and 
geriatric patients who may have difficulty swallowing traditional tablets or capsules as previously 
noted in this review. Soluleaves
TM films can also be formulated to stick to the mucous membranes 
and to release the active ingredients gradually over 15 minutes. 
 
7.2 WaferTabTM  
WaferTab™ combines pharmaceutical actives into an ingestible oral thin film. The system offers 
rapid dissolution and release of actives when there is contact with saliva in the mouth. The film 
produced can be flavoured for additional improvement in palatability [66, 92]. The WaferTabTM 
system is versatile and can be adopted in innovative ways of drug design, and facilitating multiple 
films with different actives to be bonded together. 
 
7.3 XGELTM 
XGEL™  is a Meldex trademark which it uses in all its film delivery systems and ingestible 
formulation technologies [34, 92, 126]. XGEL™ film delivers distinctive product benefits for 
healthcare and pharmaceutical products and is non-animal derived.  
 
7.4 FoamburstTM  
Foamburst™  is a special modification of the Soluleaves™ technology in which an inert gas is 
injected into the film in the production stage [34, 56, 67, 127]. This results in a film with a 
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honeycombed structure, which dissolves quickly giving a fresh mouth sensation. Foamburst™’s 
patency was granted in September 2004.  
 
7.5 Rapidfilm®  
The proprietary Rapidfilm® technology is a cutting-edge, mucoadhesive, fast dissolving oral 
dosage form and is based on water-soluble polymers and is a patented and commercial technology 
developed by German based company, Tesa Labtec GmBH [14]. The films typically have a size 
range of 3-9 cm2 and a thickness of 50 - 500 µm and the design can vary from single to multi-layer 
systems. It is a fast disintegrating film which releases the drug rapidly in the mouth and leads to 
fast systemic absorption of drugs. Rapidfilm® can incorporate a maximum of 30 mg of the API 
and can either be packaged in boxes or in the RapidCard® which is designed in the format of 
credit-card. Among the several generic Rx Rapidfilm® products, Ondansetron Rapidfilm® 
obtained its marketing authorization from the EU in March 2010, as the world’s first 
pharmaceutical product to be approved based on the oral dissolvable film technology. The product 
is marketed in Europe by Norgine under the tradename Setofilm® and in Canada by Takeda under 
the tradename Ondisolve® [14]. 
 
8 BENEFITS OF FAST-DISSOLVING ORAL THIN FILMS 
8.1 Advantages over the conventional dosage forms 
Oral thin films disintegrate and dissolve more quickly than the traditional or conventional solid 
oral dosage forms. These films are very portable and less friable hence the probability of it getting 
damaged is lower when compared to fast dissolving tablets and capsules [15]. With regard to drug 
stability, fast dissolving films are more desirable than the corresponding fast disintegrating tablets 
[11]. The packaging integrity of oral thin films is better than in liquids and other solid dosage 
forms in terms of environmental impact. Even some of the preservatives used in liquids dosage 
forms are not suitable for use in paediatrics. Fast dissolving films overcome challenges such as the 
cumbersomeness of shaking bottles containing liquid formulations to achieve accurate dose 




8.2 Clinical merits 
Fast dissolving films present with a high degree of elegance and are very appealing. These films 
are appropriate for administration in paediatrics, geriatrics and even the uncooperative such as 
mental health patients [22]. Oral thin films can also be useful where a rapid onset of action is 
desired including; coughing, motion sickness, asthma, bronchitis and sudden episodes of allergic 
attacks. They are easy to administer without choking especially for patients with swallowing 
difficulties. Oral films can be administered anywhere without using water and once it is 
administered it becomes difficult to spit out especially for children. Fast dissolving films release 
the medicament faster and therefore achieve better absorption and have the potential of evading 
the first pass effect if absorbed through the buccal mucosa [54]. By avoiding the first pass effect, 
it is possible to reduce the dose of drug which would, in turn, minimise the subsequent side-effects 
[11]. With the formulation design of oral thin films, there are opportunities for taste-masking of 
unpalatable drugs to improve overall acceptability and compliance [128]. 
 
8.3 Marketing advantage 
In term of commercial value, companies in the oral thin film manufacturing industry are presented 
with opportunities to extend the revenue lifespans of products or drugs nearing patent expiration. 
The award of exclusive marketing right to the new dosage forms would help in expanding their 
revenue margins [59].  
 
9 FUTURE PERSPECTIVES 
Oral thin films have a wide range of potential future applications not just in the pharmaceutical 
industry but also the nutraceutical and cosmeceutical industries with a future prospect of 
generating huge financial benefits through manufacturers ability to extend their products 
patent life cycles, and therefore will continue to attract interest from all the major stakeholders 
including patients, clinicians, academic researchers, pharmaceutical industries and regulatory 
agencies.  The use of oral thin films is expected to contribute towards improved compliance and 
drug therapy outcomes in paediatric and geriatric patients. This will be driven in part by the new 
regulatory requirements for these vulnerable patient groups to be taken into consideration from the 
point of drug discovery and development rather than the conventional reformulation and titration 
31 
 
from normal adult dosage forms. Another key driving force will be the increasing number of the 
geriatric demographic within patient populations worldwide.  
 
10 EXECUTIVE SUMMARY  
Oral thin film technology  
 This review provided an overview of the need for oral thin films; the material and 
patient considerations in the design, formulation and characterization of oral thin films.  
 It also showcased the benefits of oral thin film technology and the potential it presents, 
especially in drug delivery in paediatric and geriatric patients. 
General attributes  
 Oral thin films are more user-friendly than conventional dosage forms, such as tablets, 
capsules and liquids; due to the many associated challenges including non-compliance, 
lower bioavailability, and inconvenience in administration.  
 Oral thin films are easier to administer and swallow without the need for water, they ensure 
faster and better drug absorption into the bloodstream.  
 Oral thin films combine the advantages of both solid and liquid oral dosage forms. These 
include being more portable than syrups, capsules and tablets and therefore less expensive 
in terms of freight costs. Therefore oral thin films are generally more cost-effective than 
the traditional or conventional dosage forms. 
Manufacture of oral thin films 
 Oral thin films can integrate most available drugs, although low dose micronized drugs are 
the most ideal. Water-soluble polymers are used to form the matrix of oral thin films and 
other components include; plasticizers, surfactants, permeation enhancers, saliva 
stimulating, colouring, thickening, sweetening and flavouring agents.  
 The acceptance oral thin films by patients is essential to its compliance. Practically, most 
of the excipients used in their formulation have been used in traditional dosage forms such 
as tablets and are allowed for use in food and neutraceuticals. Good appearance, acceptable 
taste and palatability as well as a good mouthfeel are essential patient considerations of 




Methods of manufacture of fast dissolving oral thin films 
 Solvent casting is the widely used method for the manufacture of oral thin films while the 
HME method is an innovative alternative to formulation of oral thin films, in particular its 
ability to mask bitter taste of drugs without use of taste masking agents and also avoiding 
use of organic solvents. 
Regulatory requirements of fast dissolving thin films 
 Although the EMA and FDA have recently provided guidelines for industry, especially in 
development of formulations for vulnerable patient groups such as paediatric and geriatric 
populations, more research is required to establish global standards since most of the 
reported studies vary greatly in the methodology and approaches and it is difficult to tell 
which is most appropriate. 
 Parameters used in the characterization of oral thin films include; surface pH and swelling 
index, adequate moisture content and surface morphology, good mechanical properties and 
acceptable organoleptic indices, uniformity in weight and thickness, as well as in vitro 
disintegration, dissolution and in vivo pharmacokinetic profiles are important for meeting 
the required specifications. 
Benefits of fast dissolving oral thin films 
 Fast dissolving oral thin films have two key benefits; the first is for the patients which 
helps improve clinical efficacy and patient compliance, while the second benefit 
relates to commercial advantage it brings to pharmaceutical industry, through 
extending of patent life cycles for their drug portfolios. 
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